
The START Center for Cancer Research (“START”) is the world’s largest early phase site network, fully dedicated to oncology clinical research. Throughout our history, START has provided hope to cancer patients in global community practices by offering "Hope Through Access” to cutting edge trials throughout the United States and Europe.
The Sr. Manager of Physician (Principal Investigator) Recruitment is responsible for developing and executing START's physician recruitment strategy. This role leads the full-cycle recruitment of oncology physicians and physician-investigators across START's global network of clinical research sites.
The successful candidate will possess deep expertise in physician recruitment, an established network within oncology and cancer research communities, and a demonstrated ability to identify, engage, and recruit high-performing physician specialists. This individual will serve as a strategic advisor to executive leadership on physician workforce planning, talent market intelligence, and long-term recruitment strategy.
This role is accountable for sourcing, attracting, recruiting, and onboarding physicians who advance START's mission of accelerating cancer drug development and expanding patient access to innovative therapies.
This is a remote role. The salary range for this role is $110,000 - $130,000. However, base pay may vary depending on multiple individualized factors including market location, job-related knowledge, skills, and experience.
Work Hours: M-F, 8am-5pm
Location: Remote
Essential Responsibilities
Physician (Principal Investigator) Recruitment
Strategic Talent Pipeline Development
Oncology & Clinical Research Market Engagement
Executive Partnership
Recruitment Analytics & Operations
Required Education and Experience
Preferred Education and Experience:
Physical and Travel Requirements
Best-in-Class Benefits and Perks
We value the time, talent, and dedication our employees bring to START. Our commitment to your well-being and growth is reflected in a competitive compensation package—based on experience—along with comprehensive benefits designed to support you both personally and professionally:
More About START
START clinical trial sites have conducted more than 1,000 early-phase clinical trials, including dozens of therapies that were approved by the FDA or EMA. START represents the world’s largest roster of early-phase principal investigators across its Network of clinical trial sites.
Learn more at STARTresearch.com.
Ready to be part of a team changing the future of cancer treatment?
Join us in our mission to conquer cancer, one clinical trial at a time. Your expertise and dedication can help us bring hope and healing to patients worldwide. Please submit your application online.
We are an equal opportunity employer that welcomes and encourages diversity in the workplace. We do not discriminate on the basis of race, color, religion, marital status, age, national origin, ancestry, physical or mental disability, medical condition, pregnancy, genetic information, gender, sexual orientation, gender identity or expression, veteran status, or any other status protected under federal, state, or local law.

Deeply rooted in community oncology centers globally, the START Center for Cancer Research ("START") provides patients with access to specialized Phase 1 clinical trials for novel anti-cancer agents. With research sites in the United States and in Spain, Portugal, and Ireland, START’s clinical trial sites have conducted more than 1,500 early phase clinical trials, including for 45 therapies that have gained FDA/EMA approval. Founded in Texas in 2007, START today boasts 30+ Principal Investigators (PIs) across its worldwide clinical trial sites. With over 100,000+ square feet of world-class research facilities, START offers patients comprehensive treatment plans that include multi-specialty services, genetic profiling of tumors, targeted therapies, state-of-the-art treatment technology, and advanced access to clinical research options. START is committed to accelerating passage from trials to treatments, and to delivering hope to patients, families, and physicians around the world.